Evidence map›Paper›PMID 27402487›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2017

Oral Bioavailability and Mass Balance Studies of a Novel Anti-arrhythmic Agent Sulcardine Sulfate in Sprague-Dawley Rats and Beagle Dogs.

You-Li Lu, Shui-Jun Li, Gang-Yi Liu, Xiao-Chuan Li, Ding Yang, Jing-Ying Jia, Meng-Qi Zhang, Hong-Chao Zheng, Chen Yu, Fu Zhu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

You-Li LuCentral Laboratory, Shanghai Xuhui Central Hospital / Zhongshan - Xuhui Hospital, Fudan University / Shanghai Clinical Center, Chinese Academy of Sciences, Shanghai, 200031, China.
Shui-Jun LiCentral Laboratory, Shanghai Xuhui Central Hospital / Zhongshan - Xuhui Hospital, Fudan University / Shanghai Clinical Center, Chinese Academy of Sciences, Shanghai, 200031, China.
Gang-Yi LiuCentral Laboratory, Shanghai Xuhui Central Hospital / Zhongshan - Xuhui Hospital, Fudan University / Shanghai Clinical Center, Chinese Academy of Sciences, Shanghai, 200031, China.
Xiao-Chuan LiDepartment of Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Ding YangWuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan, 430071, China.
Jing-Ying JiaCentral Laboratory, Shanghai Xuhui Central Hospital / Zhongshan - Xuhui Hospital, Fudan University / Shanghai Clinical Center, Chinese Academy of Sciences, Shanghai, 200031, China.
Meng-Qi ZhangCentral Laboratory, Shanghai Xuhui Central Hospital / Zhongshan - Xuhui Hospital, Fudan University / Shanghai Clinical Center, Chinese Academy of Sciences, Shanghai, 200031, China.
Hong-Chao ZhengCentral Laboratory, Shanghai Xuhui Central Hospital / Zhongshan - Xuhui Hospital, Fudan University / Shanghai Clinical Center, Chinese Academy of Sciences, Shanghai, 200031, China.
Chen YuCentral Laboratory, Shanghai Xuhui Central Hospital / Zhongshan - Xuhui Hospital, Fudan University / Shanghai Clinical Center, Chinese Academy of Sciences, Shanghai, 200031, China.
Fu ZhuCentral Laboratory, Shanghai Xuhui Central Hospital / Zhongshan - Xuhui Hospital, Fudan University / Shanghai Clinical Center, Chinese Academy of Sciences, Shanghai, 200031, China.
Yi-Ping WangDepartment of Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China. ypwang@mail.shcnc.ac.cn.
Fudan University · CNShanghai Xuhui Central Hospital · CNChinese Academy of Sciences · CNShanghai Institute of Materia Medica · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesSulcardine sulfate is a newly developed candidate drug used to control arrhythmias. The aim of this research was to investigate the pharmacokinetics, bioavailability and excretion characteristics of sulcardine in animals.

methodsSprague-Dawley rats were orally and intravenously given sulcardine at 20 and 40 mg/kg. Beagle dogs were also orally and intravenously dosed at 10 mg/kg. Both [

resultsSulcardine was rapidly eliminated in rats after dosing. The oral bioavailability was 34-35 % in rats, while a higher exposure was observed in dogs (bioavailability = 62.7 %). More than 90 % of dosed sulcardine was recovered, and approximately 20-40 % of the dose excreted into urine as the original form, and the remaining was found in feces and bile, most of which (about 40 %) was transformed into metabolites. No difference was observed between sexes. Metabolism may occur to a large extent after oral administration in rats but to a smaller extent in dogs.

conclusionsSulcardine was extensively absorbed in both rats and dogs after oral administration. The mass balance data indicated that sulcardine was widely metabolized in rats after oral administration.

Indexed as

Administration, OralAnimalsAnti-Arrhythmia AgentsBileBiological AvailabilityChromatography, High Pressure LiquidDogsFecesFemaleRatsRats, Sprague-DawleySulfuric Acid EstersTandem Mass SpectrometryUrineAnti-Arrhythmia Agentssulcardine sulfateSulfuric Acid Esters

Identifiers

PMID27402487
OpenAlexW2461333458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.